IntelGenx Technologies Corp. (IGXT) Launches Forfivo XL™

IntelGenx Technologies is a Montreal based company devoted to developing its novel and innovative proprietary technologies for enhanced drug delivery. The company makes use of its proprietary drug delivery technologies to improve existing drug compounds with proven efficacy and safety and, in conjunction with strategic development and distribution partners, reintroduce these drug compounds to the market as branded products with improved deliverability and efficacy.

On October 9, 2012, IntelGenx made a significant stride when its Forfivo XL™ product was made available by prescription in the USA. IntelGenx’s product Forfivo XL™ is indicated for treatment of Major Depressive Disorder (MDD) and is currently the only extended-release bupropion HCI product to provide once-daily, 450mg dose in a single tablet. The company’s Forfivo XL™ utilizes buproprin as the active ingredient, similar to another well-known antidepressant, Wellbutrin XL®. Previously, patients in the US requiring a 450mg dose of bupropion were required to take multiple tablets to achieve the dose requirement. However, with Forfivo XL™ now available in the US, these patients can simplify their dosing regimen to a single Forfivo XL tablet, once-daily.

Dr. Horst G. Zerbe, President and CEO of IntelGenx, stated, “Until today, physicians in the US treating their MDD patients with high-dose bupropion have had to use multiples of the lower strength, 150mg and 300mg, products. With the US commercial launch of Forfivo XL, physicians can now prescribe a simpler and more convenient single-pill 450mg dose of bupropion to better meet the needs of their MDD patients. We feel that the combination of market need and the targeted marketing approach applied by our commercial partner Edgemont Pharmaceuticals will make Forfivo XL a successful product.”

On August, 7, 2012, IntelGenx recently announced financial results for the three and six month periods ended June 30, 2012. In addition to IntelGenx’s financials, the announcement also highlighted recent business developments, primarily pertaining to its anti-migraine product VersaFilm (rizatriptan) and Forfivo XL™.

IntelGenx reported cash of $3.1 million as of June 30, 2012, a decrease of approximately $0.1 million when compared to its cash position at June 2011. Revenue of $0.1 million and total expenses of $1.3 million for the first half of 2012 remained relatively unchanged when compared to revenue of $0.1 and total expenses of $1.3 for the first half of 2011.

For more information on IntelGenx Technologies, visit www.intelgenx.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html